CA11-19: a tumor marker for the detection of colorectal cancer
CA11-19: a tumor marker for the detection of colorectal cancer
复制标题
DOI：
10.1016/j.gie.2015.06.041
复制
发表时间：
2016-03-01
影响因子：
7.7
通讯作者：
Fritsche, Herbert A.
中科院分区：
文献类型：
--
作者：
Overholt, Bergein F.;Wheeler, Donald J.;Fritsche, Herbert A.
背景和目的：结直肠癌（CRC）仍然是美国癌症死亡的第二大常见原因。使用肿瘤相关抗原的血液检查有助于诊断CRC。然而，更高的灵敏度和特异性需要之前，可接受的肿瘤抗原血液检测CRC是临床上有用的。本研究描述了CA 11 -19血清肿瘤抗原检测CRC.Methods的酶联免疫吸附试验的诊断准确性：血清标本从522结肠镜检查证实的主题机构审查委员会批准的研究。对标本进行盲法编码。CA 11 -19水平通过使用酶联免疫吸附测定分析测定。结果列表正常，增生性息肉，良性胃肠道，腺瘤性息肉和CRC的类别的基础上，他们的最终diagnosis.Results：当截断值为6.4单位/mL的正常使用，CA 11 -19水平升高128 131 CRC科目，观察到的灵敏度为98%（95%置信区间，93.1%-99.5%）。87%的正常人（90/103）和83%的良性胃肠道疾病（185/223）中发现正常水平。结论：CA 11 -19是诊断结直肠癌的血清学肿瘤标志物，其敏感性为98%，特异性为84%。这种高灵敏度意味着该测试将检测44例CRC中的43例。对于50岁以上的人群，其阳性预测值为3.6%，阴性预测值为99.98%。需要更多的前瞻性研究来进一步阐明CA 11 -19作为CRC诊断辅助手段的用途。
Background and Aim: Colorectal cancer (CRC) remains the second most frequent cause of cancer deaths in the United States. Blood tests using tumor-related antigens aid in diagnosing CRC. However, higher sensitivity and specificity are needed before an acceptable tumor antigen blood test for CRC is clinically useful. This study describes the diagnostic accuracy of an enzyme-linked immunosorbent assay for the CA11-19 serologic tumor antigen for the detection of CRC.Methods: Serum specimens were obtained from 522 colonoscopy-confirmed subjects in institutional review board-approved studies. Specimens were blind coded. CA11-19 levels were determined by using enzyme-linked immunosorbent assay analysis. The results were tabulated for categories of normal, hyperplastic polyps, benign GI, adenomatous polyps, and CRC based on their final diagnosis.Results: When a cutoff of 6.4 units/mL for normal is used, the CA11-19 level was elevated in 128 of 131 of CRC subjects, for an observed sensitivity of 98% (95% confidence interval, 93.1%-99.5%). Normal levels were found in 87% of normal subjects (90/103) and 83% of those with benign GI diseases (185/223). When combined, this yields an observed specificity of 84% (95% confidence interval, 80.0%-87.9%).Conclusion: CA11-19 is a serologic tumor marker for the diagnosis of CRC with a sensitivity of 98% and specificity of 84%. This high sensitivity means that this test will detect 43 of 44 cases of CRC presented. For those older than 50 years of age, it has a positive predictive value of 3.6% and a negative predictive value of 99.98%. Additional prospective studies are needed to further clarify the use of CA11-19 as an aid in the diagnosis of CRC.